Clinicopathological characterization of next-generation sequencing detected mutations in lung cancers-a single-center experience

BACKGROUND: Despite many advances in molecular procedures many lung cancer patients do not receive full panel testing. This can limit the comprehensive understanding of their disease and potentially hinder personalized treatment options. METHODS: In this retrospective analysis, we used results from next-generation sequencing (NGS) testing of 154 patients with adenocarcinoma (AC) or squamous cell carcinoma (SCC) of the lung treated at the University Hospital, Ludwig-Maximilians Universität (LMU) Munich between 2018 and 2021. We compared different clinicopathological features and patients' baseline characteristics with results of NGS testing. We used t-test and analysis of variance (ANOVA) to compare metric- and

• Walter, J.
• Tufman, A.
• Kumbrink, J.
• Neumann, J.
• Kahnert, K.
• Sellmer, L.
• Jung, A.
• Behr, J.
• Kauffmann-Guerrero, D.